Repression of Mn-superoxide Dismutase Expression by PPARγ Activation is a Potential New Approach for

• 作 者: AlanPremKumar;
• 机 构: Yong Loo Lin School of Medicine National University of Singapore Singapore
• 出 处: (BITs 3rd Annual World Cancer Congress-2010, Breast Cancer C
• 发表日期: 2010年期

　　An approach to inhibit proliferation and increase cell death in breast cancer cell lines has given hope for the development of a new class of anticancer drugs.These new class of drugs are activators of peroxisome proliferator-activated receptor gamma (PPARy).In addition to its endogenous ligand (15dPGJ2), several synthetic thiazolidinedione ligands (rosiglitazone and pioglitazone) are already in clinical use for the treatment of type 2 diabetes.Breast cancer cells express high levels of PPARγ, whereas normal breast cells express only a low level of this receptor.This suggested a possible role for active PPARγ as an anti-tumor agent in breast cancer.Recent studies report siRNA-suppression of mitochondrial manganese-dependent superoxide dismutase (MnSOD) expression leads to decrease in breast cancer cells invasive property and cells sensitization to anti-cancer drugs.